Chimerix Company Profile (NASDAQ:CMRX)

About Chimerix

Chimerix logoChimerix, Inc. (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available. Brincidofovir is an investigational oral nucleotide analog that has shown spectrum antiviral activity against over five families of double-stranded deoxyribonucleic acid (dsDNA) viruses that affect humans. CMX157, is its second clinical-stage nucleotide analog, uses the same lipid technology as brincidofovir to deliver high intracellular concentrations of the potent antiviral drug, tenofovir. Tenofovir is marketed under the brand name Viread. The Company has discovered, developed and selected a clinical candidate, CMX669, for BK virus and cytomegalovirus.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CMRX
  • CUSIP:
Key Metrics:
  • Previous Close: $5.68
  • 50 Day Moving Average: $5.30
  • 200 Day Moving Average: $4.93
  • 52-Week Range: $3.49 - $7.73
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.44
  • P/E Growth: 0.00
  • Market Cap: $256.59M
  • Outstanding Shares: 46,315,000
  • Beta: 1.62
  • Net Margins: -1,451.99%
  • Return on Equity: -32.09%
  • Return on Assets: -30.80%
  • Current Ratio: 26.47%
  • Quick Ratio: 26.47%
Additional Links:
Companies Related to Chimerix:

Analyst Ratings

Consensus Ratings for Chimerix (NASDAQ:CMRX) (?)
Ratings Breakdown: 1 Sell Rating, 5 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $7.86 (38.33% upside)

Analysts' Ratings History for Chimerix (NASDAQ:CMRX)
DateFirmActionRatingPrice TargetDetails
1/11/2017FBR & CoReiterated RatingHold$8.00View Rating Details
8/18/2016Piper Jaffray CompaniesSet Price TargetBuy$12.00View Rating Details
8/9/2016J P Morgan Chase & CoReiterated RatingHold$7.00View Rating Details
3/1/2016Citigroup Inc.Reiterated RatingHoldView Rating Details
2/23/2016William BlairLower Price TargetMarket Perform$12.00 -> $8.00View Rating Details
2/23/2016Barclays PLCDowngradeOverweight -> Equal Weight$12.00 -> $6.00View Rating Details
2/22/2016Morgan StanleyDowngradeEqual Weight -> Underweight$8.00 -> $5.00View Rating Details
1/3/2016Brean CapitalDowngradeHoldView Rating Details
1/3/2016Cowen and CompanyDowngradeHoldView Rating Details
1/3/2016Stifel NicolausDowngradeHoldView Rating Details
12/30/2015EmpireReiterated RatingEqual WeightView Rating Details
12/30/2015Janney Montgomery ScottLower Price TargetNeutral$14.00View Rating Details
9/8/2015Cantor FitzgeraldReiterated RatingBuy$57.00View Rating Details
(Data available from 2/22/2015 forward)


Earnings History for Chimerix (NASDAQ:CMRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016Q3($0.39)($0.37)ViewListenView Earnings Details
8/8/2016Q2($0.51)($0.39)$1.98 million$1.80 millionViewN/AView Earnings Details
5/9/2016Q1($0.66)($0.57)$2.79 million$1.20 millionViewN/AView Earnings Details
2/29/2016Q415($0.14)($0.82)$8.07 million$3.10 millionViewListenView Earnings Details
11/5/2015Q315($0.59)($0.70)$5.01 million$2.27 millionViewListenView Earnings Details
8/6/2015Q215($0.58)($0.59)$1.37 million$4.10 millionViewListenView Earnings Details
5/11/2015Q115($0.59)($0.54)$1.19 million$1.20 millionViewListenView Earnings Details
3/6/2015Q414($0.51)($0.52)$1.20 millionViewListenView Earnings Details
11/7/2014Q314($0.41)($0.47)$1.19 millionViewN/AView Earnings Details
8/7/2014Q214($0.44)($0.39)ViewN/AView Earnings Details
5/9/2014Q1 14($0.36)($0.39)$0.85 million$0.78 millionViewN/AView Earnings Details
3/7/2014Q413($0.41)($0.31)$1.19 million$0.88 millionViewN/AView Earnings Details
11/14/2013Q3($0.38)($0.26)ViewListenView Earnings Details
8/14/2013Q2 2013($0.40)($0.91)$1.91 million$0.81 millionViewN/AView Earnings Details
5/13/2013Q1 2013($2.43)($22.58)$1.00 million$1.80 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Chimerix (NASDAQ:CMRX)
Current Year EPS Consensus Estimate: $-1.72 EPS
Next Year EPS Consensus Estimate: $-1.65 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.80)($0.45)($0.67)
Q2 20162($0.49)($0.48)($0.49)
Q3 20162($0.36)($0.35)($0.36)
Q4 20162($0.39)($0.35)($0.37)
(Data provided by Zacks Investment Research)


Dividend History for Chimerix (NASDAQ:CMRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Chimerix (NASDAQ:CMRX)
Insider Ownership Percentage: 10.50%
Institutional Ownership Percentage: 68.66%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/28/2016Ernest MarioDirectorSell100,000$4.64$464,000.00View SEC Filing  
9/15/2016John M LeonardDirectorSell5,000$5.03$25,150.00View SEC Filing  
8/29/2016M Michelle BerreyInsiderBuy22,417$4.47$100,203.99View SEC Filing  
6/24/2016Ernest MarioDirectorBuy50,000$3.70$185,000.00View SEC Filing  
6/24/2016M Michelle BerreyCEOBuy13,188$3.69$48,663.72View SEC Filing  
5/13/2016Ernest MarioDirectorBuy10,000$4.53$45,300.00View SEC Filing  
5/11/2016Ernest MarioDirectorBuy25,000$4.85$121,250.00View SEC Filing  
5/10/2016Ernest MarioDirectorBuy800$4.76$3,808.00View SEC Filing  
3/16/2016Ernest MarioDirectorBuy25,000$5.06$126,500.00View SEC Filing  
3/15/2016Ernest MarioDirectorBuy20,000$5.13$102,600.00View SEC Filing  
3/1/2016Martha J DemskiDirectorBuy10,000$4.89$48,900.00View SEC Filing  
12/29/2015Ernest MarioDirectorBuy125,000$7.09$886,250.00View SEC Filing  
11/2/2015Martha J. DemskiDirectorSell1,126$41.35$46,560.10View SEC Filing  
10/1/2015Martha J. DemskiDirectorSell2,000$37.68$75,360.00View SEC Filing  
9/1/2015Martha J. DemskiDirectorSell2,000$48.18$96,360.00View SEC Filing  
8/21/2015John M LeonardDirectorBuy1,000$47.38$47,380.00View SEC Filing  
7/17/2015Timothy W TrostCFOSell28,000$50.00$1,400,000.00View SEC Filing  
7/1/2015Martha J DemskiDirectorSell2,000$46.03$92,060.00View SEC Filing  
6/1/2015Martha J DemskiDirectorSell2,000$41.58$83,160.00View SEC Filing  
5/1/2015Martha J DemskiDirectorSell2,000$34.71$69,420.00View SEC Filing  
3/2/2015Martha J DemskiDirectorSell2,000$40.18$80,360.00View SEC Filing  
2/2/2015Martha J DemskiDirectorSell2,000$38.38$76,760.00View SEC Filing  
1/2/2015Martha J DemskiDirectorSell2,000$41.08$82,160.00View SEC Filing  
11/5/2014John M LeonardDirectorBuy4,000$29.00$116,000.00View SEC Filing  
9/25/2014Timothy W TrostCFOSell5,000$27.75$138,750.00View SEC Filing  
9/11/2014James NiedelDirectorSell1,099,949$29.39$32,327,501.11View SEC Filing  
9/9/2014Sanderling Venture Partners V,Major ShareholderSell122,950$29.28$3,599,976.00View SEC Filing  
9/8/2014Timothy WollaegerDirectorSell100,000$24.54$2,454,000.00View SEC Filing  
9/5/2014Ernest MarioDirectorBuy10,000$23.19$231,900.00View SEC Filing  
8/25/2014Timothy W TrostCFOSell5,000$25.13$125,650.00View SEC Filing  
7/25/2014Timothy W TrostInsiderSell5,000$22.35$111,750.00View SEC Filing  
6/25/2014Timothy W TrostCFOSell5,000$22.74$113,700.00View SEC Filing  
5/27/2014Ernest MarioDirectorBuy10,000$14.22$142,200.00View SEC Filing  
5/27/2014M Michelle BerreyInsiderBuy14,065$14.22$200,004.30View SEC Filing  
5/27/2014Timothy W TrostCFOSell5,000$17.41$87,050.00View SEC Filing  
4/25/2014Timothy W TrostInsiderSell5,000$18.67$93,350.00View SEC Filing  
3/25/2014Timothy W TrostCFOSell5,000$25.37$126,850.00View SEC Filing  
2/25/2014Timothy W TrostCFOSell5,000$19.29$96,450.00View SEC Filing  
1/27/2014Timothy W TrostCFOSell5,000$18.26$91,300.00View SEC Filing  
12/26/2013Timothy W TrostCFOSell5,000$15.21$76,050.00View SEC Filing  
12/13/2013Ernest MarioDirectorBuy5,000$13.90$69,500.00View SEC Filing  
12/9/2013Rodman L DrakeDirectorBuy1,000$14.35$14,350.00View SEC Filing  
11/25/2013Ernest MarioDirectorBuy8,000$15.20$121,600.00View SEC Filing  
11/19/2013Ernest MarioDirectorBuy7,500$15.25$114,375.00View SEC Filing  
11/15/2013Rodman L DrakeDirectorBuy1,000$15.56$15,560.00View SEC Filing  
10/25/2013Timothy W TrostCFOSell5,000$16.04$80,200.00View SEC Filing  
10/23/2013Leaf Ventures Ii L.P. NewMajor ShareholderSell585,602$15.51$9,082,687.02View SEC Filing  
10/23/2013Vii L P CanaanDirectorSell674,771$15.51$10,465,698.21View SEC Filing  
8/30/2013Ernest MarioDirectorBuy5,064$15.82$80,112.48View SEC Filing  
8/26/2013Ernest MarioDirectorBuy5,960$17.20$102,512.00View SEC Filing  
8/23/2013M Michelle BerreyInsiderBuy5,540$18.70$103,598.00View SEC Filing  
8/20/2013Ernest MarioDirectorBuy4,040$17.48$70,619.20View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Chimerix (NASDAQ:CMRX)
DateHeadline logoChimerix Announces Final Data from AdVise Trial of Brincidofovir at BMT Tandem Meetings (NASDAQ:CMRX) - February 22 at 11:17 AM logo8:06 am Chimerix announces the presentation of final data from the AdVise trial of brincidofovir for the treatment of adenovirus infection in allogeneic hematopoietic cell transplant recipients at the BMT Tandem Meetings; results show highe (NASDAQ:CMRX) - February 22 at 11:17 AM
News IconIs The Sell-Side Predicting That Chimerix, Inc. (NASDAQ:CMRX) Will Move Higher? - Winfield Review (NASDAQ:CMRX) - February 17 at 3:36 PM
News IconWatching the Technicals on Shares of Chimerix Inc. (CMRX) - Benton Bulletin (NASDAQ:CMRX) - February 17 at 3:36 PM
News IconTechnical Focus on Shares of Chimerix Inc. (CMRX) - BVN (NASDAQ:CMRX) - February 17 at 3:36 PM
News IconConsensus Take: Chimerix, Inc. (NASDAQ:CMRX) Earnings & Ratings Watch - Aiken Advocate (NASDAQ:CMRX) - February 16 at 11:13 AM
News IconAre Analysts Optimistic About Where Chimerix, Inc. (NASDAQ:CMRX) is Heading? - Winfield Review (NASDAQ:CMRX) - February 16 at 11:13 AM
News IconShares to Watch: Indicator Update on Chimerix Inc. (CMRX) - Rives Journal (NASDAQ:CMRX) - February 9 at 9:48 PM
News IconLevels in Review for Chimerix, Inc. (NASDAQ:CMRX) - The Tribune (NASDAQ:CMRX) - January 30 at 5:14 PM
News IconChimerix, Inc. (NASDAQ:CMRX) Quarterly EPS Projection At $-0.39 - Stock Observer (NASDAQ:CMRX) - January 30 at 5:14 PM
News IconNews Impact Score Of Chimerix, Inc. (NASDAQ:CMRX) At 77 | Stock ... - Stock Observer (NASDAQ:CMRX) - January 30 at 7:06 AM
News IconInvestor Watch: Volatility Review for Chimerix, Inc. (NASDAQ:CMRX) - Gilbert Daily (NASDAQ:CMRX) - January 30 at 7:05 AM
News IconInvestors are Keeping Tabs on Chimerix, Inc. (NASDAQ:CMRX) - The Tribune (NASDAQ:CMRX) - January 27 at 5:46 PM
News IconInvestor Corner: Checking in on Shares of Chimerix Inc. (CMRX) - Sherwood Daily (NASDAQ:CMRX) - January 26 at 10:27 PM
News IconGoPro, Inc. (NASDAQ:GPRO) (NASDAQ:CMRX) - January 26 at 3:32 AM
News IconFirst Week of CMRX March 17th Options Trading (NASDAQ:CMRX) - January 25 at 5:29 PM
News IconChimerix Inc CMRX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:CMRX) - January 24 at 4:58 PM logoWill Chimerix (CMRX) Continue to Surge Higher? (NASDAQ:CMRX) - January 24 at 4:58 PM
News IconMixed Picture to Start the Week (NASDAQ:CMRX) - January 24 at 2:43 AM logoVIVUS : Research Reports Coverage on Biotech Stocks -- Emergent BioSolutions, Chimerix, VIVUS, and RXi Pharma (NASDAQ:CMRX) - January 18 at 4:44 PM
News IconWill The Needle Move For Chimerix, Inc. (NASDAQ:CMRX) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:CMRX) - January 17 at 8:55 AM
News IconNews Impact Score Of Chimerix, Inc. (NASDAQ:CMRX) Set At 100 - Stock Observer (NASDAQ:CMRX) - January 14 at 9:31 PM
News IconEPS Of Chimerix, Inc. (NASDAQ:CMRX) At $-0.39 - Stock Observer (NASDAQ:CMRX) - January 9 at 10:32 PM
News IconChimerix, Inc. (NASDAQ:CMRX) News Impact Score At 80 - Stock Observer (NASDAQ:CMRX) - January 8 at 9:20 PM logoCHIMERIX INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:CMRX) - January 6 at 4:49 PM logoChimerix Announces Preliminary Data from Ongoing Phase 1 Dose Escalation Study of Intravenous Brincidofovir in Healthy Subjects (NASDAQ:CMRX) - January 6 at 4:49 PM logoChimerix (CMRX) Names Randall Lanier as CSO; Roy Ware CMTO (NASDAQ:CMRX) - January 5 at 9:56 PM logo4:30 pm Chimerix appoints Randall Lanier, PhD, as Chief Science Officer (NASDAQ:CMRX) - January 5 at 9:55 PM logoChimerix Appoints Randall Lanier, PhD as Chief Science Officer, and Roy W. Ware, PhD, MBA as Chief Manufacturing and Technology Officer (NASDAQ:CMRX) - January 5 at 4:54 PM logoChimerix to Present at the 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:CMRX) - January 4 at 5:24 PM
News IconChimerix, Inc. (NASDAQ:CMRX) EPS At $-0.39 - Stock Observer (NASDAQ:CMRX) - January 2 at 4:41 PM
News IconChimerix, Inc. (NASDAQ:CMRX) News Impact Score At 100 - Stock Observer (NASDAQ:CMRX) - January 1 at 5:49 AM logoInsider Trading Activity Chimerix, Inc. (NASDAQ:CMRX) – Director Sold 100000 shares of Stock - Market Exclusive (NASDAQ:CMRX) - December 30 at 9:49 PM logoInsider Trading Activity Chimerix, Inc. (NASDAQ:CMRX) – Director Sold 100,000 shares of Stock (NASDAQ:CMRX) - December 30 at 4:49 PM logoSentiments And Ratings Alert: Chimerix, Inc. (NASDAQ:CMRX) - Investor Newswire (NASDAQ:CMRX) - December 27 at 4:36 PM
News IconEPS Of Chimerix, Inc. (NASDAQ:CMRX) Set At $-0.39 - Stock Observer (NASDAQ:CMRX) - December 20 at 8:32 AM
News IconThe annual Dividend for Chimerix, Inc. (NASDAQ:CMRX) is $0 ... - The Newburgh Press (NASDAQ:CMRX) - December 20 at 8:32 AM
News IconNews Impact Score Of Chimerix, Inc. (NASDAQ:CMRX) At 80 - Stock Observer (NASDAQ:CMRX) - December 17 at 4:33 PM
News IconIndicator Level Summary for Chimerix Inc. (CMRX) - Yankee Analysts (NASDAQ:CMRX) - December 16 at 9:49 PM
News IconRelative Strength Index Review on Shares of Chimerix Inc. (CMRX) - Yankee Analysts (NASDAQ:CMRX) - December 15 at 3:24 AM
News IconUpdate on Valuation Formula's For Chimerix, Inc. (NASDAQ:CMRX) - The Business Journal (NASDAQ:CMRX) - December 12 at 12:27 PM
News IconNews Impact Score Of Chimerix, Inc. (NASDAQ:CMRX) At 100 - Stock Observer (NASDAQ:CMRX) - December 11 at 11:33 AM
News IconStock Tracker: Trend Analysis on Chimerix Inc. (CMRX) - Yankee Analysts (NASDAQ:CMRX) - December 11 at 11:33 AM
News IconChart Trading: Viewing CCI and ADX Levels for Chimerix Inc. (CMRX) - Yankee Analysts (NASDAQ:CMRX) - December 9 at 9:44 PM logoHere is What Hedge Funds Think About Chimerix Inc (CMRX) (NASDAQ:CMRX) - December 8 at 4:01 PM
News IconEPS Of Chimerix, Inc. (NASDAQ:CMRX) Set At $-0.41 - Stock Observer (NASDAQ:CMRX) - December 5 at 5:07 PM
News IconADX Update on These Shares: Chimerix Inc. (CMRX) - Yankee Analysts (NASDAQ:CMRX) - December 5 at 5:07 PM logoETFs with exposure to Chimerix, Inc. : December 5, 2016 (NASDAQ:CMRX) - December 5 at 12:27 PM
News IconLooking at the Technicals for Chimerix Inc. (CMRX) - Yankee Analysts (NASDAQ:CMRX) - December 1 at 4:30 PM
News IconChartists Taking a Look at Shares of Chimerix Inc. (CMRX) - MicroCap Wired (NASDAQ:CMRX) - November 23 at 9:10 PM


What is Chimerix's stock symbol?

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

Where is Chimerix's stock going? Where will Chimerix's stock price be in 2017?

7 analysts have issued 1 year target prices for Chimerix's stock. Their forecasts range from $5.00 to $12.00. On average, they anticipate Chimerix's share price to reach $7.86 in the next twelve months.

When will Chimerix announce their earnings?

Chimerix is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

What are analysts saying about Chimerix stock?

Here are some recent quotes from research analysts about Chimerix stock:

  • According to Zacks Investment Research, "Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. " (2/16/2017)

  • FBR & Co analysts commented, "We recently had an opportunity to meet with CMRX’s management to discuss the company’s outlook for 2017. CMRX updated us on the progress it has made with its pipeline, with several milestones stated for 2017. It is advancing the intravenous (IV) formulation of brincidofovir (BCV) to address CMV, the BK virus, and other DNA viral infections. Additionally, the company updated progress on CMX521, which is in preclinical studies for norovirus. We expect an IND to be filed in the back half of this year." (1/11/2017)

Who owns Chimerix stock?

Chimerix's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (14.99%), EcoR1 Capital LLC (3.06%), Opaleye Management Inc. (2.53%), Arrowpoint Asset Management LLC (2.26%), State Street Corp (1.62%) and Dimensional Fund Advisors LP (1.05%). Company insiders that own Chimerix stock include Ernest Mario, John M Leonard, M Michelle Berrey, Martha J Demski and Timothy W Trost.

Who sold Chimerix stock? Who is selling Chimerix stock?

Chimerix's stock was sold by a variety of institutional investors in the last quarter, including Bogle Investment Management L P DE and AQR Capital Management LLC. Company insiders that have sold Chimerix stock in the last year include Ernest Mario and John M Leonard.

Who bought Chimerix stock? Who is buying Chimerix stock?

Chimerix's stock was acquired by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Opaleye Management Inc., Dimensional Fund Advisors LP, Arrowpoint Asset Management LLC, Two Sigma Investments LP, Cigna Investments Inc. New, Moloney Securities Asset Management LLC and GSA Capital Partners LLP. Company insiders that have bought Chimerix stock in the last two years include Ernest Mario, John M Leonard, M Michelle Berrey and Martha J Demski.

How do I buy Chimerix stock?

Shares of Chimerix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Chimerix stock cost?

One share of Chimerix stock can currently be purchased for approximately $5.68.

Chimerix (NASDAQ:CMRX) Chart for Wednesday, February, 22, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Chimerix (NASDAQ:CMRX)

Earnings History Chart

Earnings by Quarter for Chimerix (NASDAQ:CMRX)

Dividend History Chart

Dividend Payments by Quarter for Chimerix (NASDAQ:CMRX)

Last Updated on 2/22/2017 by Staff